Goldman Sachs Innovate Equity ETF (ARCA: GINN)

Latest News for Goldman Sachs Innovate Equity ETF (ARCA:GINN)

Goldman Sachs Innovate Equity ETF

Duke Energy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) short percent of float has fallen 10.66% since its last report. The company recently reported that it has 8.40 million shares sold short, which is 1.09% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.2 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Duke Energy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714077022_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Duke Energy has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Duke Energy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Duke Energy's peer group average for short interest as a percentage of float is 2.53%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

(DUK) - Analyzing Duke Energy's Short Interest

Alphabet Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) reported financial results for the first quarter Thursday after the bell. Here's a look at the&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/GOOG" rel="noreferrer noopener">key metrics from the quarter</a>.
Q1 Earnings:&nbsp;Google parent Alphabet said its first-quarter revenue increased 15% year-over-year to $80.539 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $78.594 billion. The company reported quarterly earnings of $1.89 per share, beating analyst estimates of $1.51 per share.
Alphabet has now beat analyst estimates on both the top and bottom lines in five consecutive quarters, according to earnings data from&nbsp;<a target="_blank" href="http://pro.benzinga.com" rel="noreferrer noopener">Benzinga Pro</a>.
Google Search revenue was $46.156 billion in the quarter, YouTube advertising revenue&nbsp;came in at&nbsp;$8.09&nbsp;billion and Google Cloud revenue totaled $9.574 billion.
"Our results in the first quarter reflect strong performance from Search, YouTube&nbsp;and&nbsp;Cloud. We are well under way with our Gemini era&nbsp;and&nbsp;there's&nbsp;great momentum across the company. Our leadership in AI research and&nbsp;infrastructure,&nbsp;and our global product&nbsp;footprint,&nbsp;position us well for the next wave of AI innovation," said&nbsp;Sundar Pichai, CEO of Alphabet.
Alphabet's board authorized an additional share repurchase program of up to $70 billion.&nbsp;
The company also announced its first-ever quarterly dividend. Alphabet's board declared a cash dividend of 20 cents per share to be paid on June 17 to shareholders of record as of June 10. Alphabet noted that it plans to pay quarterly cash dividends moving forward.
Alphabet did not provide forward guidance in the earnings release. Management will hold a conference call to discuss these results at 4:30 p.m. ET.
Check This Out:&nbsp;<a target="_blank" href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38427221/top-3-tech-stocks-that-could-lead-to-your-biggest-gains-in-april" rel="noreferrer noopener">Top 3 Tech Stocks That Could Lead To Your Biggest Gains In April</a>
GOOG Price Action:&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/GOOG" rel="noreferrer noopener">Alphabet shares</a>&nbsp;were up 12.2% after hours at $177.11 at the time of publication, according to&nbsp;<a target="_blank" href="https://benzinga.grsm.io/gxjhpowx7zks" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Shutterstock.

Earnings

News

Movers

Tech

GOOG

GOOGL

Alphabet Q1 Earnings: Revenue Beat, EPS Beat, $70B Buyback, First-Ever Dividend, AI Leadership And More

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/BLOZF">Cannabix Technologies</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLOZF#OTC">BLOZF</a>) shares closed up 35.40% at $0.44</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 33.56% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 22.86% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 17.95% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CNPOF">RIV Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNPOF#OTC">CNPOF</a>) shares closed up 14.29% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/BMMJ">Body and Mind</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed up 11.11% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 10.24% at $1.83</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed up 8.56% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CARA">Cara Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares closed up 4.23% at $0.70</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed up 3.37% at $0.27</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed down 26.67% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">Cansortium</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 9.84% at $0.17</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 9.60% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 9.06% at $0.28</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed down 6.38% at $2.20</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed down 6.26% at $10.18</li>
<li><a href="https://www.benzinga.com/quote/ACB">Aurora Cannabis</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) shares closed down 6.25% at $6.71</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed down 5.94% at $4.75</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 5.74% at $33.50</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed down 5.60% at $11.80</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed down 5.34% at $1.95</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 4.35% at $1.75</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 3.80% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed down 3.37% at $0.19</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed down 3.20% at $0.20</li>
<li><a href="https://www.benzinga.com/quote/GENE">Genetic Technologies</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENE#NASDAQ">GENE</a>) shares closed down 3.11% at $2.18</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed down 3.03% at $1.27</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

BLOZF

BMMJ

CARA

CNBX

CNPOF

CNTMF

CRBP

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CWBHF

CXXIF

FFNTF

GBHPF

GENE

GRWG

GTBIF

KAYS

MRMD

NWVCF

OILFF

RMHB

TCNNF

TGIFF

TLRY

UGRO

Marijuana Stock Movers For April 25, 2024

Rogers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROG#NYSE">ROG</a>) reported quarterly earnings of $0.58 per share which beat the analyst consensus estimate of $0.55 by 5.45 percent. This is a 33.33 percent decrease over earnings of $0.87 per share from the same period last year. The company reported quarterly sales of $213.400 million which beat the analyst consensus estimate of $210.000 million by 1.62 percent. This is a 12.49 percent decrease over sales of $243.847 million the same period last year.

Earnings Beats

Rogers Q1 2024 Adj EPS $0.58 Beats $0.55 Estimate, Sales $213.400M Beat $210.000M Estimate

COPT Defense (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDP#NYSE">CDP</a>) reported quarterly earnings of $0.62 per share which beat the analyst consensus estimate of $0.61 by 1.64 percent. This is a 5.08 percent increase over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $193.266 million which beat the analyst consensus estimate of $170.519 million by 13.34 percent. This is a 15.38 percent increase over sales of $167.501 million the same period last year.

COPT Defense Q1 2024 FFO $0.62 Beats $0.61 Estimate, Sales $193.266M Beat $170.519M Estimate

WIIM

PINS

Pinterest shares are trading higher in sympathy with Snap, which reported better-than-expected Q1 financial results and issued Q2 revenue guidance above estimates

CubeSmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBE#NYSE">CUBE</a>) reported quarterly earnings of $0.64 per share which missed the analyst consensus estimate of $0.65 by 1.54 percent. The company reported quarterly sales of $261.406 million which beat the analyst consensus estimate of $242.356 million by 7.86 percent. This is a 1.90 percent increase over sales of $256.528 million the same period last year.

Earnings Misses

CUBE

CubeSmart Q1 2024 FFO $0.64 Misses $0.65 Estimate, Sales $261.406M Beat $242.356M Estimate

Toughbuilt Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBLT#NASDAQ">TBLT</a>), announced that on April 19, 2024, it received a staff determination notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that since the Company has not yet filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the "Annual Report"), the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"). &nbsp;
ToughBuilt has 60 calendar days from April 19, 2024, to submit a plan to Nasdaq outlining the Company's anticipated steps to regain compliance with the Listing Rule. The Company plans to submit the plan explaining the strategy to make the required SEC filings, and to regain compliance with the Listing Rule.
The Company is committed to fulfilling its reporting obligations and anticipates filing the Annual Report at the earliest opportunity, with plans to keep Nasdaq fully informed throughout this process.

TBLT

Toughbuilt Industries Announces Receipt Of Nasdaq Delinquency Notice

ResMed shares are trading higher after the company reported better-than-expected Q3 financial results.

Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>, "Aligos")))), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced an ePoster flash session presentation at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2024, being held April 27-30, 2024 in Barcelona, Spain.
The presentation highlights ALG-097558 Phase 1 data showing that single (up to 2000 mg) and multiple (up to 800 mg Q12 for 7 days) doses of this potent, pan-coronavirus protease inhibitor were well tolerated in healthy volunteers with a PK profile supporting twice daily ritonavir-free dosing without a food effect.
"We are pleased to present these ALG-097558 data, which further highlight the best-in-class potential of this pan-coronavirus protease inhibitor and its substantial differentiation versus current standard of care coronavirus antiviral drugs like nirmatrelvir/ritonavir (PAXLOVIDTM)," said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics. "These data further demonstrate that Aligos has developed a robust clinical pipeline of three potentially best-in-class drug candidates. We look forward to continuing to advance ALG-097558 for current and potential future pandemics with the financial support of various external funding sources, including government agencies."
Details of the presentation are as follows:
<ul>
<li>ePoster Flash Session Presentation Title: Safety and pharmacokinetics of single and multiple ascending doses of ALG-097558, a pan-coronavirus protease inhibitor, in healthy volunteers
<ul>
<li>Presented by Denisa Wilkes, MD, MSc, CPM, Medical Director, Hammersmith Medicines Research</li>
<li>April 28, 2024 at 8:30am CEST &nbsp;</li>
</ul>
</li>
</ul>
The presentation will be available on the <a href="https://www.globenewswire.com/Tracker?data=rRwyfWd_0O9bvSJYSKZUPIdqmn166ZGzKtEpiKM2pKTi_5GfHqhiulXhIWl2JsZIHySE4sbNDZHaSpIzAGfmDwxm1IEsHQzqu7SE5jw_jW48l3n3MIBCmgfOJvaLaLJoMLccQ7_qUIOZs_rAL6JCGOKGB8OjCkm4ND_9Mro7wnI=">Scientific Presentations &amp; Conferences</a> section of the Aligos website (<a href="https://www.globenewswire.com/Tracker?data=OV10l7IjOGXMWCt3eLBLHyvgSVh4WFPr6uJ9ocDlW_QzB64mFdmsKT8J-xHn1pGYQmdCPAZ1cQn7TNyrkPuLrIU6IY7VHlDNdllxDCszD_tFV_lB5SbgB3kPyKOPt8c2xBgiCxjuTeIhd2oWgAJE8dS5M4MzE4Z2LxRhP_Id2ungaz27IiDVMBS5SKgJ4uMzL0Aya3Bzo7ICTAjYy24PxxK5m3sSSi3ukL07MDro8AM=">www.aligos.com</a>) after the live event.

Biotech

General

ALGS

Aligos Therapeutics Presents Clinical Data At ESCMID 2024 From The ALG-097558 Phase 1 Study

TFI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFII#NYSE">TFII</a>) reported quarterly earnings of $1.24 per share which missed the analyst consensus estimate of $1.36 by 8.82 percent. This is a 6.77 percent decrease over earnings of $1.33 per share from the same period last year. The company reported quarterly sales of $1.87 billion which missed the analyst consensus estimate of $1.90 billion by 1.33 percent. This is a 1.11 percent increase over sales of $1.85 billion the same period last year.

TFII

TFI International Q1 EPS $1.24 Misses $1.36 Estimate, Sales $1.87B Miss $1.90B Estimate

TEAM

Atlassian shares are trading lower. The company reported Q3 financial results.

Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares are trading lower after the company reported worse-than-expected first-quarter sales results and issued earnings guidance below estimates on Thursday. Here's a <a href="https://www.benzinga.com/pressreleases/24/04/b38443217/intel-reports-first-quarter-2024-financial-results">look at the details. </a>
The Details:
Intel reported quarterly earnings of 18 cents per share, which beat the analyst consensus estimate of 14 cents by 28.57%. 
Quarterly sales came in at $12.72 billion, which missed the analyst consensus estimate of $12.78 billion by 0.44% and represents an 8.61% increase over sales of $11.71 billion from the same period last year.
Revenue by segment in the first quarter and the year-over-year change was:
<figure class="wp-block-table is-style-regular"> 
<table>
<tbody>
<tr>
<td>Client Computing Group (CCG)</td>
<td>&nbsp;</td>
<td>$7.5 billion</td>
<td>&nbsp;</td>
<td>up</td>
<td></td>
<td>31%</td>
</tr>
<tr>
<td>Data Center and AI (DCAI)</td>
<td>&nbsp;</td>
<td>$3.0 billion</td>
<td>&nbsp;</td>
<td>up</td>
<td></td>
<td>5%</td>
</tr>
<tr>
<td>Network and Edge (NEX)</td>
<td>&nbsp;</td>
<td>$1.4 billion</td>
<td>&nbsp;</td>
<td>down</td>
<td></td>
<td>8%</td>
</tr>
<tr>
<td>Intel Foundry</td>
<td>&nbsp;</td>
<td>$4.4 billion</td>
<td>&nbsp;</td>
<td>down</td>
<td></td>
<td>10%</td>
</tr>
</tbody>
</table>
</figure>
&#8220;We are making steady progress against our priorities and delivered a solid quarter,&#8221; said Pat Gelsinger, Intel CEO.&nbsp;
&#8220;Strong innovation across our client, edge and data center portfolios drove double-digit revenue growth in Intel Products. With Intel 3 in high-volume production, leading-edge semiconductors are being manufactured in the U.S. for the first time in almost a decade and we are on track to regain process leadership next year as we grow Intel Foundry,&#8221; he added.
&#8220;We are confident in our plans to drive sequential growth throughout the year as we accelerate our AI solutions and maintain our relentless focus on execution, operational discipline and shareholder value creation in a dynamic market,&#8221; Gelsinger said. 
Outlook:&nbsp;
Intel sees second-quarter earnings of 10 cents per share, versus the 10 cent estimate, and revenue in a range of $12.5 billion to $13.5 billion, versus the $12.68 billion estimate.&nbsp;
Related News: <a href="https://www.benzinga.com/news/earnings/24/04/38441140/s-p-global-reports-q1-results-raises-revenue-guidance">S&amp;P Global Reports Q1 Results, Raises Revenue Guidance</a>
INTC Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Intel shares are down 8.7% after-hours at $31.96 at the time of publication Thursday.
Image: Monticello from Shutterstock

INTC

Intel Shares Fall On Q1 Revenue Miss, Weak Q2 EPS Guidance

Guidance

Skechers Raises FY24 Sales Outlook From $8.60B-$8.80B To $8.725B-$8.875B (Est $8.781B), EPS From $3.65-$3.85 To $3.95-$4.10 (Est $3.90)

Columbia Banking System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) reported quarterly earnings of $0.65 per share which beat the analyst consensus estimate of $0.53 by 22.64 percent. This is a 41.3 percent increase over earnings of $0.46 per share from the same period last year. The company reported quarterly sales of $473.719 million which missed the analyst consensus estimate of $480.364 million by 1.38 percent. This is a 10.31 percent increase over sales of $429.433 million the same period last year.

COLB

Columbia Banking System Q1 2024 Adj EPS $0.65 Beats $0.53 Estimate, Sales $473.719M Miss $480.364M Estimate

GILD

Gilead Sciences shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

Dividends

Comfort Systems Raises Dividend From $0.25 To $0.30

Alphabet Board Initiated Cash Dividend Program, Declared Dividend Of $0.20/Share

VINC

Vincerx Pharma shares are trading lower after the company announced a proposed underwritten public offering of common stock and warrants.

LivaNova PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIVN#NASDAQ">LIVN</a>), a market-leading medical technology company, today announced that its wholly-owned U.S. subsidiary, LivaNova USA, Inc., is providing notice to U.S. patients regarding a cybersecurity incident that was initially disclosed by the Company on November 20, 2023.
The incident resulted in a disruption to portions of the Company's information technology systems. Promptly after detecting the issue on November 19, 2023, LivaNova began an investigation with assistance from external cybersecurity experts and coordinated with law enforcement. The Company took action to remediate the issue, such as taking certain systems offline, and resumed manufacturing as previously disclosed. In the course of its investigation, the Company determined that its systems were first accessed by an unauthorized party around October 26, 2023.
On April 10, 2024, LivaNova learned that the unauthorized party obtained certain identifiable personal information of U.S. patients. While the Company is continuing to analyze the nature and scope of the affected information, the Company is aware that the information, which varied by impacted individual, included data such as name, contact information (e.g., phone number, email and postal address), Social Security number, date of birth, medical information (e.g., treatment, condition, diagnosis, prescription, physician, medical record number and device serial number), and health insurance information.
On April 25, 2024, LivaNova posted notice of this incident on its website. The Company is sending notice to affected U.S. patients for whom it has contact information. The Company's notice of this incident includes information on how affected U.S. patients can enroll in complimentary identity protection and credit monitoring services. LivaNova encourages affected patients in the U.S. to remain vigilant for incidents of fraud and identity theft by reviewing their account statements and monitoring their free credit reports, and to remain alert for unsolicited communications involving personal information.
Affected U.S. patients who have questions or would like additional information about this issue can contact (833) 931-5100 toll-free, Monday through Friday, 8 a.m. to 8 p.m. CT (excluding major U.S. holidays). Please reference engagement number B121304 when calling. Additional information is available at<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.livanova.com&amp;esheet=53957159&amp;newsitemid=20240425016136&amp;lan=en-US&amp;anchor=www.livanova.com&amp;index=1&amp;md5=ed7e6d50fccbd2788b2c725efc7b38da">www.livanova.com</a>.

LIVN

LivaNova Issues Notice To U.S. Patients Regarding Cybersecurity Incident Initially Disclosed By The Company On November 20, 2023